Der blev observeret større blødninger hos 3, 4% af patienterne i fondaparinuxgruppen over for hos 2, 4% i dalteparingruppen. m
Major bleeding was observed in 3.4% of the patients in the fondaparinux group and in 2.4% of the dalteparin group.